Anika Therapeutics Files 8-K on Financials
Ticker: ANIK · Form: 8-K · Filed: Oct 31, 2024 · CIK: 898437
| Field | Detail |
|---|---|
| Company | Anika Therapeutics, Inc. (ANIK) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Anika Therapeutics dropped an 8-K on Oct 31st detailing their financial results. Check it out.
AI Summary
Anika Therapeutics, Inc. filed an 8-K on October 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending October 31, 2024. The company is incorporated in Delaware and headquartered in Bedford, Massachusetts.
Why It Matters
This 8-K filing provides an update on Anika Therapeutics' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- Anika Therapeutics, Inc. (company) — Registrant
- October 31, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Bedford, Massachusetts (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on Anika Therapeutics, Inc.'s 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was made on October 31, 2024.
What is Anika Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 32 Wiggins Avenue, Bedford, Massachusetts 01730.
What is the company's fiscal year end?
Anika Therapeutics, Inc.'s fiscal year ends on December 31.
What is the SIC code for Anika Therapeutics, Inc.?
The Standard Industrial Classification code is 3841, for SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-10-31 07:20:36
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share ANIK NASDAQ Global Select Mar
Filing Documents
- f8k_103124.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 184KB
- 0001171843-24-005923.txt ( ) — 409KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_103124_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. On October 31, 2024, Anika Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of Anika Therapeutics, Inc. dated October 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Anika Therapeutics, Inc. Date: October 31, 2024 By: /s/ Cheryl R. Blanchard Cheryl R. Blanchard President and Chief Executive Officer